Kérourédan Olivia, Jallon Léonard, Perez Paul, Germain Christine, Péli Jean-François, Oriez Dominique, Fricain Jean-Christophe, Arrivé Elise, Devillard Raphaël
CHU de Bordeaux, Pôle d'Odontologie et de Santé Buccale, 33000, Bordeaux, France.
INSERM, Bioingénierie Tissulaire, U1026, 33076, Bordeaux, France.
Trials. 2017 Mar 28;18(1):141. doi: 10.1186/s13063-017-1883-x.
Irreversible pulpitis is a highly painful inflammatory condition of the dental pulp which represents a common dental emergency. Recommended care is partial endodontic treatment. The dental literature reports major difficulties in achieving adequate analgesia to perform this emergency treatment, especially in the case of mandibular molars. In current practice, short-course, orally administered corticotherapy is used for the management of oral pain of inflammatory origin. The efficacy of intraosseous local steroid injections for irreversible pulpitis in mandibular molars has already been demonstrated but resulted in local comorbidities. Oral administration of short-course prednisolone is simple and safe but its efficacy to manage pain caused by irreversible pulpitis has not yet been demonstrated. This trial aims to evaluate the noninferiority of short-course, orally administered corticotherapy versus partial endodontic treatment for the emergency care of irreversible pulpitis in mandibular molars.
METHODS/DESIGN: This study is a noninferiority, open-label, randomized controlled clinical trial conducted at the Bordeaux University Hospital. One hundred and twenty subjects will be randomized in two 1:1 parallel arms: the intervention arm will receive one oral dose of prednisolone (1 mg/kg) during the emergency visit, followed by one morning dose each day for 3 days and the reference arm will receive partial endodontic treatment. Both groups will receive planned complete endodontic treatment 72 h after enrollment. The primary outcome is the proportion of patients with pain intensity below 5 on a Numeric Scale 24 h after the emergency visit. Secondary outcomes include comfort during care, the number of injected anesthetic cartridges when performing complete endodontic treatment, the number of antalgic drugs and the number of patients coming back for consultation after 72 h.
This randomized trial will assess the ability of short-term corticotherapy to reduce pain in irreversible pulpitis as a simple and rapid alternative to partial endodontic treatment and to enable planning of endodontic treatment in optimal analgesic conditions.
ClinicalTrials.gov, identifier: NCT02629042 . Registered on 7 December 2015. (Version n°1.1 28 July 2015).
不可逆性牙髓炎是牙髓的一种剧痛性炎症状态,是常见的牙科急症。推荐的治疗方法是部分牙髓治疗。牙科文献报道,在进行这种急症治疗时,要实现充分镇痛存在很大困难,尤其是在下颌磨牙的情况下。在当前的临床实践中,短期口服皮质激素疗法用于治疗炎症性口腔疼痛。骨内局部注射类固醇治疗下颌磨牙不可逆性牙髓炎的疗效已经得到证实,但会导致局部并发症。短期口服泼尼松龙简单且安全,但其治疗不可逆性牙髓炎所致疼痛的疗效尚未得到证实。本试验旨在评估短期口服皮质激素疗法与部分牙髓治疗在治疗下颌磨牙不可逆性牙髓炎急症方面的非劣效性。
方法/设计:本研究是一项在波尔多大学医院进行的非劣效性、开放标签、随机对照临床试验。120名受试者将按1:1随机分为两个平行组:干预组在急症就诊时口服一剂泼尼松龙(1mg/kg),随后连续3天每天早晨服用一剂;参照组接受部分牙髓治疗。两组在入组72小时后均接受计划性的完整牙髓治疗。主要结局是急症就诊24小时后疼痛强度在数字评分量表上低于5的患者比例。次要结局包括治疗过程中的舒适度、进行完整牙髓治疗时注射的麻醉药筒数量、镇痛药数量以及72小时后复诊的患者数量。
这项随机试验将评估短期皮质激素疗法减轻不可逆性牙髓炎疼痛的能力,作为部分牙髓治疗的一种简单快速替代方法,并能够在最佳镇痛条件下规划牙髓治疗。
ClinicalTrials.gov,标识符:NCT02629042。于2015年12月7日注册。(2015年7月28日第1.1版)